Postnatal Corticosteroids To Prevent Bronchopulmonary Dysplasia
Erik A. Jensen, Kristi L. Watterberg
Abstract
Bronchopulmonary dysplasia (BPD) is a common, severe chronic respiratory disease that affects very preterm infants. In utero and postnatal exposure to proinflammatory stimuli contribute to the pathophysiology of BPD. Corticosteroids, because of their potent anti-inflammatory properties, may decrease respiratory morbidity and reduce the risk of BPD in very preterm infants. However, these medications can have adverse effects on the developing brain and other organ systems. This review examines current evidence on the risks and benefits of postnatal corticosteroids used to prevent BPD in preterm infants.
Topics & Concepts
Bronchopulmonary dysplasiaMedicineProinflammatory cytokinePathophysiologyIn uteroAdverse effectPediatricsIntensive care medicineRespiratory systemDiseaseFetusPregnancyInflammationInternal medicineGestational ageGeneticsBiologyNeonatal Respiratory Health ResearchInfant Development and Preterm CareCongenital Diaphragmatic Hernia Studies